Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma.
Myc
osteosarcoma
prognostic marker
therapeutic target
tissue microarray
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
11
2019
accepted:
03
04
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Over the past four decades, outcomes for osteosarcoma patients have plateaued as there have been few emerging therapies showing clinical results. Thus, the identification of novel biomarkers and therapeutic strategies are urgently needed to address these primary obstacles in patient care. Although the Myc-oncogene has known roles in oncogenesis and cancer cell growth, its expression and function in osteosarcoma are largely unknown. Expression of Myc was determined by Western blotting of osteosarcoma cell lines and patient tissues, and by immunohistochemistry of a unique osteosarcoma tissue microarray (TMA) constructed from 70 patient samples with extensive follow-up data. Myc specific siRNA and inhibitor 10058-F4 were applied to examine the effect of Myc inhibition on osteosarcoma cell proliferation. The clonogenicity and migration activity was determined by clonogenic and wound-healing assays. A mimic Myc was significantly overexpressed in human osteosarcoma cell lines compared with normal human osteoblasts, and also highly expressed in fresh osteosarcoma tissues. Higher Myc expression correlated significantly with metastasis and poor prognosis. Through the addition of Myc specific siRNA and inhibitor, we significantly reduced Myc protein expression, resulting in decreased osteosarcoma cell proliferation. Inhibition of Myc also suppressed the migration, clonogenicity, and spheroid growth of osteosarcoma cells. Our results support Myc as an emerging prognostic biomarker and therapeutic target in osteosarcoma therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Over the past four decades, outcomes for osteosarcoma patients have plateaued as there have been few emerging therapies showing clinical results. Thus, the identification of novel biomarkers and therapeutic strategies are urgently needed to address these primary obstacles in patient care. Although the Myc-oncogene has known roles in oncogenesis and cancer cell growth, its expression and function in osteosarcoma are largely unknown.
METHODS
METHODS
Expression of Myc was determined by Western blotting of osteosarcoma cell lines and patient tissues, and by immunohistochemistry of a unique osteosarcoma tissue microarray (TMA) constructed from 70 patient samples with extensive follow-up data. Myc specific siRNA and inhibitor 10058-F4 were applied to examine the effect of Myc inhibition on osteosarcoma cell proliferation. The clonogenicity and migration activity was determined by clonogenic and wound-healing assays. A mimic
RESULTS
RESULTS
Myc was significantly overexpressed in human osteosarcoma cell lines compared with normal human osteoblasts, and also highly expressed in fresh osteosarcoma tissues. Higher Myc expression correlated significantly with metastasis and poor prognosis. Through the addition of Myc specific siRNA and inhibitor, we significantly reduced Myc protein expression, resulting in decreased osteosarcoma cell proliferation. Inhibition of Myc also suppressed the migration, clonogenicity, and spheroid growth of osteosarcoma cells.
CONCLUSION
CONCLUSIONS
Our results support Myc as an emerging prognostic biomarker and therapeutic target in osteosarcoma therapy.
Identifiants
pubmed: 32426053
doi: 10.1177/1758835920922055
pii: 10.1177_1758835920922055
pmc: PMC7222246
doi:
Types de publication
Journal Article
Retracted Publication
Langues
eng
Pagination
1758835920922055Subventions
Organisme : NCI NIH HHS
ID : U01 CA151452
Pays : United States
Commentaires et corrections
Type : RetractionIn
Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Oncotarget. 2014 Sep 15;5(17):7805-19
pubmed: 25138053
J Clin Oncol. 2010 May 20;28(15):2625-34
pubmed: 20404250
Cancer Discov. 2015 Oct;5(10):1024-39
pubmed: 26382145
Cell Stem Cell. 2009 Aug 7;5(2):141-9
pubmed: 19664987
Semin Cancer Biol. 2006 Aug;16(4):313-7
pubmed: 16935001
Oncogene. 2003 Sep 18;22(40):6151-9
pubmed: 13679853
J Clin Invest. 2014 Jan;124(1):398-412
pubmed: 24316975
Cell Syst. 2018 Mar 28;6(3):282-300.e2
pubmed: 29596783
Cancer Discov. 2019 Jan;9(1):46-63
pubmed: 30266815
Acta Biochim Biophys Sin (Shanghai). 2015 Mar;47(3):183-91
pubmed: 25630654
Exp Hematol. 2011 Aug;39(8):817-28.e1
pubmed: 21640157
Biofabrication. 2017 Aug 03;9(3):032003
pubmed: 28707624
Exp Hematol. 2006 Nov;34(11):1480-9
pubmed: 17046567
Int J Biochem Cell Biol. 2019 Mar;108:7-16
pubmed: 30639430
Anticancer Drugs. 2007 Feb;18(2):161-70
pubmed: 17159602
Signal Transduct Target Ther. 2018 Feb 23;3:5
pubmed: 29527331
Oncol Lett. 2014 Sep;8(3):1355-1359
pubmed: 25120723
Genes (Basel). 2019 Mar 22;10(3):
pubmed: 30909496
Cancer Cell. 2008 Dec 9;14(6):471-84
pubmed: 19061838
EBioMedicine. 2019 Jan;39:182-193
pubmed: 30579871
Cancer Res. 2011 Aug 1;71(15):5164-74
pubmed: 21646475
Nature. 2008 Oct 2;455(7213):679-83
pubmed: 18716624
Nat Commun. 2017 Nov 23;8(1):1728
pubmed: 29170413
Semin Cancer Biol. 2006 Aug;16(4):318-30
pubmed: 16934487
Biomaterials. 2013 Nov;34(33):8459-68
pubmed: 23932296
Carcinogenesis. 2014 Aug;35(8):1671-9
pubmed: 24903340
J Intern Med. 2014 Jul;276(1):52-60
pubmed: 24645771
Cancer Res. 2005 Jun 1;65(11):4471-4
pubmed: 15930260
Acta Neuropathol. 2012 Apr;123(4):501-13
pubmed: 22139329
Nat Rev Cancer. 2014 Nov;14(11):722-35
pubmed: 25319867
J Clin Oncol. 2010 Jul 10;28(20):3360-5
pubmed: 20498406
Leuk Res. 2015 Jan;39(1):92-9
pubmed: 25443862
J Cell Biochem. 2019 Aug;120(8):14004-14016
pubmed: 30957273
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9
pubmed: 12808131
J Orthop Res. 2019 Feb;37(2):510-521
pubmed: 30488489
Cold Spring Harb Perspect Med. 2014 Jun 02;4(6):
pubmed: 24890832
Biochim Biophys Acta. 2001 Mar 21;1471(3):M135-45
pubmed: 11250069
EMBO J. 1993 Dec 15;12(13):5083-7
pubmed: 8262051
Clin Exp Metastasis. 2005;22(4):319-29
pubmed: 16170668
Cancer Treat Res. 2014;162:65-92
pubmed: 25070231
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Nat Rev Mol Cell Biol. 2008 Oct;9(10):810-5
pubmed: 18698328
Mol Ther. 2010 Apr;18(4):828-34
pubmed: 20068551
Mod Pathol. 2008 Sep;21(9):1156-67
pubmed: 18567993
Bioorg Med Chem Lett. 2009 Feb 1;19(3):807-10
pubmed: 19114306
Semin Cancer Biol. 2006 Aug;16(4):253-64
pubmed: 16904903
Gene. 2012 Feb 25;494(2):145-60
pubmed: 22227497
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3830-5
pubmed: 11891322
Cancer Res. 2010 Feb 1;70(3):859-62
pubmed: 20086171
Cell. 1993 Jan 29;72(2):233-45
pubmed: 8425220
Oncogene. 2003 Dec 8;22(56):9007-21
pubmed: 14663479
Cancer Treat Res. 2009;152:3-13
pubmed: 20213383
Genes Dev. 2003 May 1;17(9):1115-29
pubmed: 12695333
J Cell Biochem. 2008 Oct 15;105(3):670-7
pubmed: 18773413